PARP-1 regulates resistance of pancreatic cancer to TRAIL therapy.

TitlePARP-1 regulates resistance of pancreatic cancer to TRAIL therapy.
Publication TypeJournal Article
Year of Publication2013
AuthorsYuan K, Sun Y, Zhou T, McDonald J, Chen Y
JournalClinical cancer research : an official journal of the American Association for Cancer Research
Volume19
Issue17
Pagination4750-9
Date Published2013 Sep 1
Abstract

Activating extrinsic apoptotic pathways targeting death receptors (DR) using agonistic antibodies or TNF-related apoptosis-inducing ligand (TRAIL) is promising for cancer therapy. However, most pancreatic cancers are resistant to TRAIL therapy. The present studies aimed to identify combination therapies that enhance the efficacy of TRAIL therapy and to investigate the underlying mechanisms.

DOI10.1158/1078-0432.CCR-13-0516
Alternate JournalClin. Cancer Res.